Anhui Fengyuan Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of December 2022: 1.81%

Anhui Fengyuan Pharmaceutical Co Ltd (000153) has an Asset Resilience Ratio of 1.81% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anhui Fengyuan Pharmaceutical Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥80.69 Million
≈ $11.81 Million USD Cash + Short-term Investments

Total Assets

CN¥4.47 Billion
≈ $653.99 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2020)

This chart shows how Anhui Fengyuan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Anhui Fengyuan Pharmaceutical Co Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Anhui Fengyuan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 000153 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥80.69 Million 1.81%
Total Liquid Assets CN¥80.69 Million 1.81%

Asset Resilience Insights

  • Limited Liquidity: Anhui Fengyuan Pharmaceutical Co Ltd maintains only 1.81% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Anhui Fengyuan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Anhui Fengyuan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 0.50%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Neuland Laboratories Limited
NSE:NEULANDLAB
Drug Manufacturers - Specialty & Generic 9.65%
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
Drug Manufacturers - Specialty & Generic 1.18%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%

Annual Asset Resilience Ratio for Anhui Fengyuan Pharmaceutical Co Ltd (2016–2020)

The table below shows the annual Asset Resilience Ratio data for Anhui Fengyuan Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 0.19% CN¥6.99 Million
≈ $1.02 Million
CN¥3.64 Billion
≈ $532.09 Million
-0.09pp
2019-12-31 0.28% CN¥9.87 Million
≈ $1.44 Million
CN¥3.56 Billion
≈ $520.88 Million
+0.02pp
2018-12-31 0.26% CN¥7.79 Million
≈ $1.14 Million
CN¥3.01 Billion
≈ $440.16 Million
-0.23pp
2017-12-31 0.49% CN¥13.47 Million
≈ $1.97 Million
CN¥2.77 Billion
≈ $405.00 Million
-0.32pp
2016-12-31 0.81% CN¥20.06 Million
≈ $2.94 Million
CN¥2.49 Billion
≈ $364.42 Million
--
pp = percentage points

About Anhui Fengyuan Pharmaceutical Co Ltd

SHE:000153 China Drug Manufacturers - Specialty & Generic
Market Cap
$407.99 Million
CN¥2.79 Billion CNY
Market Cap Rank
#13362 Global
#3959 in China
Share Price
CN¥6.00
Change (1 day)
-2.76%
52-Week Range
CN¥5.02 - CN¥7.03
All Time High
CN¥22.93
About

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells medicines in China. The company also exports its products. Anhui Fengyuan Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Hefei, China.